Clarivate Plc

Clarivate Plc

CLVT
Clarivate PlcUS flagNew York Stock Exchange
2.21
USD
+0.01
- -
1.41BMarket Cap
Clarivate Plc
CLVT
(New York Stock Exchange)

Recent

price

2.21

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.01
3.17
3.56
2.93
2.97
3.93
3.91
3.69
3.65
3.7
Revenue per Share
-0.86
-0.79
-0.94
-0.82
-0.49
-5.97
-1.47
-0.96
-0.3
-0.21
Basic EPS, GAAP
0.02
-0.09
0.42
0.6
0.51
0.75
1.11
0.93
0.93
0.9
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.03
0.11
0.11
0.05
- -
- -
Dividend per Share
-1.28
3.42
4.58
20.39
16.2
9
7.59
8.17
7.87
7.94
Book Value per Share
-7.16
-7.18
-6.97
-10.22
-12.3
-10.2
-9.58
-7.02
-7.03
-7.02
Tangible Book Value per Share
305
305
274
429
631
676
672
694
673
661
Basic Weighted Avg Shares
918
968
974
1,254
1,877
2,660
2,629
2,557
2,455
2,447
Sales/Revenue/Turnover
-7.2
-11.52
-4.95
-2.24
3.31
10.01
10.43
9.16
7.01
7.24
Operating Margin (%)
228
237
201
303
538
710
708
727
757
756
Depreciation Expense
-264
-242
-259
-351
-270
-3,960
-911
-637
-201
-137
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-28.76
-25
-26.54
-27.96
-14.41
-148.89
-34.66
-24.9
-8.19
-5.62
Profit Margin (%)
-217
-235
-158
-276
-265
-165
-138
-189
-259
-241
Working Capital
1,968
1,930
1,693
3,562
5,550
5,078
4,784
4,572
4,359
4,315
LT Debt
1,286
1,051
1,249
9,035
11,926
6,812
5,992
5,139
4,843
4,789
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-22.5
-7.02
-3.29
-49.49
-17.65
-12.42
-3.67
-2.55
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
19
120
19
LT Borrowings
4,419
4,322
4,282
LT Finance Leases
42
38
34
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
661
641
639
Market Capitalization
2,604
2,249
1,673

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,291
1,310
1,301
Cash, Cash Equivalents & STI
319
329
232
Accounts Receivable, Net
811
822
883
Inventories
- -
- -
- -
Total Current Liabilities
1,490
1,569
1,542
Payables & Accruals
389
361
422
ST Debt
19
120
19
Deferred Revenue
952
941
1,000

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-8.58%
-5.76%
Free Cash Flow
- -
22.65%
-2.8%
Net Income, GAAP
- -
233.13%
-68.42%
Sales/Revenue/Turnover
- -
16.7%
-3.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
621
650
622
663
2,557
2025
594
621
623
617
2,455
2026
586
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.46
-0.09
- -
-0.96
2025
-0.15
-0.11
-0.04
- -
-0.3
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
- -
- -
0.05
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Clarivate Plc (NYSE: CLVT) provides trusted insights and analytics to accelerate innovation and improve health worldwide. The company offers subscription-based information services and workflow solutions; these include Web of Science for citation indexing and research discovery, Cortellis for life sciences intelligence and competitive benchmarking, Derwent for patent analytics and IP protection, ProQuest for academic and public library content, and MarkMonitor for brand protection and online trademark management. Clarivate serves academic institutions, governments, life sciences and healthcare companies, and corporations across intellectual property, life sciences, academia, and government sectors; it operates globally with a presence in over 100 countries. Founded in 2016 as a spin-off from Thomson Reuters and headquartered in London, United Kingdom, the company has no major parent but maintains key subsidiaries such as ProQuest and Clarivate Analytics entities. In late 2024, Clarivate completed the acquisition of Leerink Partners to bolster its healthcare investment banking capabilities; it also launched enhanced AI-driven features in Cortellis and Web of Science platforms amid ongoing strategic expansions into predictive analytics for drug development and IP management.

Company News

MCPAPIChat
  • Clarivate Announces Simon Webster as President of Intellectual Property Segment

  • Clarivate Introduces IPOne

  • Clarivate Introduces IPOne

  • Clarivate's IPfolio and Renewal Services Selected by IGT

  • Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform

  • Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform

  • Clarivate: Business Showed Signs Of Stabilization, But It Is Not Enough

  • Clarivate launches Web of Science Research Intelligence

  • Why Clarivate Stock Was Soaring This Week

  • Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript

  • Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics

  • Clarivate PLC (CLVT) Tops Q1 Earnings and Revenue Estimates

  • Clarivate Reports First Quarter 2026 Results

  • Clarivate Introduces Nexus Connect, the First Institutional AI Gateway to Trusted Research and Learning

  • Clarivate to Report First Quarter 2026 Results on April 29, 2026

  • Analyzing 3 E Network Technology Group (NASDAQ:MASK) and Clarivate (NYSE:CLVT)

  • Clarivate PLC (NYSE:CLVT) Receives $3.22 Average Target Price from Analysts

  • Clarivate Reveals the AI50 - the Organizations Leading Artificial Intelligence Invention

  • Clarivate: The Data Intelligence Company Flying Under the Radar

  • Clarivate Plc (CLVT) Presents at Wolfe Research FinTech Forum Transcript